GLOBAL ONCOLOGY INFORMATION SYSTEM MARKET

Comprehensive Market Analysis & Strategic Forecast  |  2024 – 2032

Executive Summary

Western Market Research Group is proud to publish its authoritative market intelligence report on the Global Oncology Information System (OIS) Market. The market was valued at USD 9.2 billion in 2024 and is projected to surge to USD 21.8 billion by 2032, reflecting a robust compound annual growth rate (CAGR) of 11.3% throughout the forecast period. This exceptional growth trajectory is driven by an accelerating global cancer burden, transformative advances in precision medicine, widespread digitisation of clinical workflows, and the integration of artificial intelligence (AI) into oncology care delivery.

Oncology Information Systems encompass integrated software, hardware, and service platforms that manage the complete oncology care continuum — from patient registration and treatment planning to dose management, drug administration, billing, outcomes analytics, and clinical trial coordination. As cancer remains the world's second-leading cause of mortality — with the World Health Organization recording 20 million new cases in 2022 — the imperative for sophisticated, interoperable oncology informatics has never been greater.

This report provides an exhaustive analysis of market dynamics, segmentation by component, deployment mode, application area, and geography, alongside competitive intelligence and a granular nine-year market forecast through 2032.

Key Market Findings

Market Valuation & Growth

•       Global OIS market valued at USD 9.2 billion in 2024; forecast to reach USD 21.8 billion by 2032 at a CAGR of 11.3%.

•       North America leads with a 36% market share; Asia-Pacific is the fastest-growing region at a CAGR of 14.2%.

•       Software components dominate, accounting for 52.2% of total market revenue in 2024.

•       Cloud-based deployment has surpassed on-premise installations, capturing 47% of the market as of 2024.

Technology & Innovation Landscape

•       AI-driven adaptive radiotherapy planning platforms are reducing treatment preparation time by up to 60%, with adoption doubling year-over-year since 2022.

•       Natural Language Processing (NLP) tools embedded within OIS platforms are automating clinical documentation, reducing oncologist administrative burden by an estimated 35%.

•       Next-generation sequencing (NGS) data integration within OIS is enabling molecular tumor board workflows and personalized treatment protocol selection.

•       Interoperability between OIS and Electronic Health Record (EHR) systems has emerged as the top procurement criterion, cited by 78% of healthcare CIOs surveyed.

•       Digital twin technology for simulating radiotherapy treatment outcomes is transitioning from research settings to commercial OIS platforms.

Epidemiological & Clinical Drivers

•       Global cancer incidence is projected to reach 35 million annual new cases by 2050 (WHO), creating sustained long-term demand for advanced oncology informatics.

•       Lung, breast, colorectal, and prostate cancers collectively represent 44% of global incidence and are primary use-case drivers for OIS adoption.

•       Radiation oncology workflows represent the largest OIS application segment at USD 3.4 billion, reflecting the capital-intensive nature of linear accelerator management.

•       Increasing clinical trial activity in oncology — comprising over 30% of all registered trials globally — is driving demand for integrated trial management modules within OIS platforms.

Healthcare Policy & Regulatory Catalysts

•       The US Centers for Medicare & Medicaid Services (CMS) value-based care initiatives are incentivising OIS adoption through quality reporting requirements tied to reimbursement.

•       The EU European Health Data Space (EHDS) regulation is mandating cross-border health data interoperability, accelerating OIS modernisation across EU member states.

•       National cancer control plans in over 100 countries now include explicit targets for digital oncology infrastructure development.

•       FDA clearances for AI-powered radiation treatment planning software increased by 47% between 2022 and 2024, validating the technology maturity of AI-integrated OIS solutions.

Market Segmentation by Component

The OIS market is analysed across four primary component categories, each with distinct growth drivers, margin profiles, and competitive dynamics.

Software remains the dominant component driven by ongoing platform upgrades, SaaS subscription transitions, and the integration of AI modules. Services, particularly managed implementation and training, deliver the most predictable recurring revenue profiles for vendors. Cloud and SaaS represent the fastest-growing component, with a projected CAGR of 18.4% through 2032 as health systems migrate legacy on-premise OIS infrastructure.

Market Segmentation by Deployment Mode

Deployment preferences are shifting rapidly toward cloud-based architectures as healthcare organisations prioritise scalability, business continuity, and reduced IT overhead.

The cloud-based segment is forecast to capture 62% of the market by 2032, up from 47% in 2024. Key enablers include the availability of FedRAMP-authorised and HIPAA-compliant cloud environments, multi-site oncology network requirements, and the growing ecosystem of cloud-native AI analytics tools that require cloud infrastructure to function at scale.

Market Segmentation by Application Area

OIS platforms serve diverse oncology specialties, each with distinct workflow requirements, regulatory considerations, and integration complexities.

Radiation oncology remains the largest application segment, underpinned by the complexity of linear accelerator scheduling, treatment plan optimisation, and dose verification workflows. The pathology and genomics segment is the fastest growing, fuelled by the proliferation of liquid biopsies, companion diagnostics, and multi-omic data integration requirements emerging from precision oncology programs.

Regional Market Analysis

Geographic distribution of OIS demand reflects differential stages of healthcare IT maturity, cancer burden, and digital transformation investment across world regions.

Asia-Pacific's exceptional growth rate is driven by China's Healthy China 2030 national cancer initiative, India's Ayushman Bharat digital health mission, and the rapid expansion of private oncology hospital chains across Southeast Asia. Government-funded national cancer centre networks in South Korea and Japan continue to procure next-generation OIS platforms at scale.

Competitive Landscape

The global OIS market is concentrated among a small number of deeply specialised vendors, with Varian Medical Systems (Siemens Healthineers) and Elekta holding commanding positions in radiation oncology OIS. The broader oncology informatics space features increasing competition from general EHR vendors extending into oncology modules, as well as emerging precision medicine and real-world data platforms.

Key competitive dynamics observed in 2023–2024 include: strategic acquisitions of AI and real-world evidence (RWE) startups by incumbent OIS vendors; intensifying competition at the EHR-OIS convergence layer; increasing customer demand for open API architectures enabling third-party module integration; and the emergence of oncology-specific data cloud platforms as a new competitive battleground.

Key Growth Drivers

Clinical & Epidemiological Drivers

•       Rising global cancer burden: 20 million new cases annually (2022), projected to reach 35 million by 2050.

•       Expansion of multidisciplinary cancer care requiring integrated information systems spanning radiology, pathology, pharmacy, and clinical oncology.

•       Growth of precision oncology: targeted therapies, immunotherapies, and CAR-T protocols require highly specialised drug management and monitoring workflows within OIS.

•       Increasing cancer survivorship populations demanding long-term treatment toxicity monitoring and survivorship care planning modules.

Technology Drivers

•       AI and machine learning integration enabling predictive toxicity modelling, automated contouring, adaptive treatment plan optimisation, and outcome prediction.

•       Cloud computing enabling real-time multi-site data aggregation across oncology networks, facilitating federated learning for AI model training without patient data transfer.

•       Interoperability standards maturation (HL7 FHIR, DICOM RT) enabling seamless integration between OIS, PACS, EHR, pharmacy, and laboratory systems.

•       Teleoncology and remote patient monitoring creating new workflow requirements for OIS platforms, particularly for at-home chemotherapy administration programs.

Policy & Commercial Drivers

•       Mandatory electronic clinical quality measure (eCQM) reporting for oncology programs in the US, EU, and increasingly in APAC jurisdictions.

•       Healthcare system consolidation creating large integrated delivery networks with the scale to justify enterprise OIS platform investments.

•       Pharmaceutical industry investment in real-world evidence generation creating commercial demand for OIS platforms with robust outcomes data capture.

•       Medical tourism growth in oncology (estimated USD 6.1 billion market) requiring internationally interoperable OIS platforms at destination health systems.

Market Challenges & Risk Factors

•       Cybersecurity vulnerabilities: oncology systems are high-value ransomware targets; 34% of US healthcare cyberattacks in 2023 affected oncology departments.

•       High implementation complexity: OIS deployment in large academic cancer centres averages 18–24 months, with total cost of ownership (TCO) frequently exceeding initial procurement estimates.

•       Data privacy regulations: GDPR (EU), HIPAA (US), and PDPA (APAC) create complex compliance requirements for cloud-hosted OIS platforms handling sensitive genomic and treatment data.

•       Workforce shortages: global scarcity of medical physicists, radiation therapists, and oncology informatics specialists constrains the pace of OIS implementation and optimisation.

•       Legacy system lock-in: many health systems operate aging proprietary OIS platforms, with migration to modern architectures requiring significant capital and workflow disruption.

•       Reimbursement uncertainty: evolving value-based care models may alter the economic case for OIS investment in markets where fee-for-service revenue tied to treatment volume is declining.

Market Forecast (2024–2032)

The following table presents the detailed market size projections, year-on-year growth rates, and key anticipated industry milestones for the Global Oncology Information System Market.

Investment & Strategic Outlook

The Global OIS market presents compelling investment and strategic opportunity across the value chain. Key themes for the 2024–2032 outlook include:

M&A Activity

•       Incumbent OIS vendors are expected to pursue acquisitions of AI/ML startups with radiation oncology, pathology imaging, and clinical decision support capabilities.

•       Health system consolidation will drive enterprise OIS renegotiations, creating opportunities for vendors offering integrated multi-specialty platform solutions.

•       Vertical integration between pharmaceutical companies and OIS vendors around real-world evidence generation platforms is an emerging strategic frontier.

Emerging Market Opportunity

•       India, Brazil, and Southeast Asia represent USD 3.2 billion in cumulative incremental OIS opportunity through 2032, largely untapped by current market leaders.

•       Affordable, cloud-native OIS solutions priced for middle-income health economies represent a significant white space opportunity.

•       Public-private partnerships in national cancer centre development — particularly in Africa and South Asia — are creating new procurement channels for OIS vendors.

About This Report

This press release summarises findings from Western Market Research Group's flagship publication: Global Oncology Information System (OIS) Market — Technology, Trends & Forecast, 2024–2032. The full 320-page report provides comprehensive market sizing, granular segmentation (component, deployment, application, end-user, geography), competitive benchmarking, technology roadmapping, regulatory landscape analysis, and strategic recommendations for OIS vendors, health system CIOs, and healthcare investors.

Research Methodology: Mixed-methods approach combining primary research (structured interviews with oncology CIOs, radiation oncologists, medical physicists, OIS product managers, and healthcare investors) with secondary data from cancer registries, healthcare IT adoption surveys, regulatory filings, and proprietary market modelling. Quantitative estimates validated against vendor revenue disclosures and institutional procurement data.

Media & Analyst Enquiries

Western Market Research Group